- Home
- CGO vs ALEC Comparison
CGO vs ALEC Comparison
Compare CGO & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- ALEC
- Stock Information
- Founded
- CGO 2004
- ALEC 2013
- Country
- CGO United States
- ALEC United States
- Employees
- CGO N/A
- ALEC N/A
- Industry
- CGO Investment Managers
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGO Finance
- ALEC Health Care
- Exchange
- CGO Nasdaq
- ALEC Nasdaq
- Market Cap
- CGO 119.4M
- ALEC 124.0M
- IPO Year
- CGO N/A
- ALEC 2019
- Fundamental
- Price
- CGO $12.21
- ALEC $3.02
- Analyst Decision
- CGO
- ALEC Buy
- Analyst Count
- CGO 0
- ALEC 8
- Target Price
- CGO N/A
- ALEC $4.50
- AVG Volume (30 Days)
- CGO 34.7K
- ALEC 1.2M
- Earning Date
- CGO 01-01-0001
- ALEC 11-05-2025
- Dividend Yield
- CGO 9.25%
- ALEC N/A
- EPS Growth
- CGO N/A
- ALEC N/A
- EPS
- CGO N/A
- ALEC N/A
- Revenue
- CGO N/A
- ALEC $81,130,000.00
- Revenue This Year
- CGO N/A
- ALEC N/A
- Revenue Next Year
- CGO N/A
- ALEC $196.86
- P/E Ratio
- CGO N/A
- ALEC N/A
- Revenue Growth
- CGO N/A
- ALEC 46.77
- 52 Week Low
- CGO $7.90
- ALEC $0.87
- 52 Week High
- CGO $10.93
- ALEC $6.37
- Technical
- Relative Strength Index (RSI)
- CGO 68.93
- ALEC 63.84
- Support Level
- CGO $12.05
- ALEC $2.71
- Resistance Level
- CGO $12.20
- ALEC $3.18
- Average True Range (ATR)
- CGO 0.17
- ALEC 0.22
- MACD
- CGO 0.04
- ALEC -0.01
- Stochastic Oscillator
- CGO 93.33
- ALEC 79.55
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.